Patents Assigned to The United States of America, as represented by the Secretary, Department of Health and Human
  • Publication number: 20250136938
    Abstract: Disclosed are methods of obtaining a cell population enriched for T cells having antigenic specificity for a cancer-specific mutation using in vitro stimulation of memory T cells. Also disclosed are related methods of isolating a T cell receptor (TCR), populations of cells, TCRs or antigen-binding portions thereof, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Application
    Filed: December 30, 2024
    Publication date: May 1, 2025
    Applicant: The United States of America,as represented by the Secretary, Department of Health and Human Servic
    Inventors: Gal Cafri, Steven A. Rosenberg
  • Publication number: 20250134897
    Abstract: Disclosed are compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods of preparation thereof, wherein R1, Xa, Xb, Xc, and Xd are as described in the specification. Further disclosed is an isotopic mixture of a compound of Formula (I), as well as a pharmaceutical composition containing a hyperpolarized compound of Formula (I). Also disclosed is a method of diagnosing or monitoring a patient suffering from cancer, the method including administering a pharmaceutical composition comprising an effective amount of a hyperpolarized ketoglutarate compound or a pharmaceutically acceptable salt thereof, and measuring the hyperpolarization of a compound of interest in the patient. Further disclosed is a method of preparing hyperpolarized ketoglutarate compounds for use in the above methods.
    Type: Application
    Filed: January 26, 2023
    Publication date: May 1, 2025
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Rolf E. SWENSON, Jessica H. ETTEDGUI-BENJAMINI, Venkatareddy SABBASANI, Deepak SAIL, Kazutoshi YAMAMOTO, Murali K. CHERUKURI
  • Publication number: 20250134907
    Abstract: Disclosed is a compound of formula (I), in which R1, R2, R3, R4, R5, X1, X2, X3, X4, and X5 are described herein. The small molecule compounds of formula (I) activate the functional activity of relaxin family peptide receptor 2 (RXFP2), thereby providing therapeutic treatments for a variety of disorders, such as a bone disorder, hypogonadism, cryptorchidism, polycystic ovary syndrome, cancer, infertility, or an ocular wound.
    Type: Application
    Filed: January 31, 2023
    Publication date: May 1, 2025
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The Florida International University Board of Trustees
    Inventors: Juan J. Marugan, Noel T. Southall, Marc Ferrer, Mark J. Henderson, Kenneth J. Wilson, Alexander I. Agoulnik, Courtney B. Myhr, Maria Esteban-Lopez, Elena Barnaeva, Xin Hu, Wenjuan Ye, Irina Agoulnik
  • Publication number: 20250127887
    Abstract: The present disclosure relates to a vaccine comprising an amphiphile having the formula S-[B]-[U]-H and at least one peptide antigen conjugate having the formula selected from [S]-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-[S], wherein the amphiphile and/or the at least one peptide antigen conjugate comprises a dendron amplifier. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, an infectious disease, a cardiovascular disease, or a neurodegenerative disease.
    Type: Application
    Filed: February 16, 2022
    Publication date: April 24, 2025
    Applicants: Barinthus Biotherapeutics North America, Inc., The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Geoffrey M. Lynn, Sarah R. Nichols, Vincent L. Coble, Andrew S. Ishizuka, Hugh Clarke Welles, Robert N. Goddu, Christopher Martin O’Brien Garliss, Ramiro Andrei Ramirez-Valdez
  • Publication number: 20250130234
    Abstract: The disclosure provides methods for carrying out Real Time Cellular Thermal Shift Assays (RT-CETSA). Also provided are molecular constructs and protein constructs for use in such assays and devices suitable for carrying out such assays. Also provided are non-parametric methods for analyzing data from RT-CETSA and other biological target engagement assays.
    Type: Application
    Filed: December 21, 2022
    Publication date: April 24, 2025
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Michael H. Ronzetti, Mark J. Henderson, Tino W. Sanchez, Samuel G. Michael, Ty C. Voss, Bolormaa Baljinnyam, Anton Simeonov
  • Patent number: 12281060
    Abstract: Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: April 22, 2025
    Assignees: The University of Chicago, The United States of America, as Represented by the Secretary, Department of Health and Human Services, President and Fellows of Harvard College, IIT Research Institute, Beth Israel Deaconess Medical Center Inc.
    Inventors: Julian Solway, Nickolai Dulin, Diane Luci, David Maloney, Chan Young Park, Jeffrey Fredberg, David McCormick, Ramaswamy Krishnan
  • Patent number: 12281336
    Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.
    Type: Grant
    Filed: May 27, 2024
    Date of Patent: April 22, 2025
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Wataru Akahata, Srinivas Rao
  • Publication number: 20250122473
    Abstract: Disclosed are methods of preparing thymic emigrant cells in vitro, isolated or purified thymic emigrant cells prepared by the methods, and pharmaceutical compositions comprising the same. Further disclosed are methods of treating or preventing a condition in a mammal comprising administering the thymic emigrant cells or pharmaceutical compositions comprising the same to the mammal.
    Type: Application
    Filed: December 18, 2024
    Publication date: April 17, 2025
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Raul E. Vizcardo, Nicholas D. Klemen, Nicholas P. Restifo
  • Patent number: 12275786
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: August 4, 2022
    Date of Patent: April 15, 2025
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kenichi Hanada, Qiong J. Wang, James C. Yang, Zhiya Yu
  • Patent number: 12275758
    Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.
    Type: Grant
    Filed: January 10, 2024
    Date of Patent: April 15, 2025
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
  • Patent number: 12268737
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Grant
    Filed: April 26, 2024
    Date of Patent: April 8, 2025
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Secretary, Department of Health and Human Services
    Inventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
  • Patent number: 12269872
    Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: April 8, 2025
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Robert Seder, Lawrence Wang, Rachel Vistein, Joseph Francica
  • Patent number: 12270738
    Abstract: Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: April 8, 2025
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen M. Hewitt, Joon-Yong Chung, Candice D. Perry, Robert A. Star
  • Patent number: 12268700
    Abstract: Disclosed is a compound of the formula (I) or (II): wherein a f are as described herein. The compounds are useful in the activation of Type II NKT cells and in treating cancer.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: April 8, 2025
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Connecticut
    Inventors: Lise H. Pasquet, Jay A. Berzofsky, Amy R. Howell, Masaki Terabe, Kaddy Camara, Stewart K. Richardson
  • Patent number: 12270881
    Abstract: Kinetic monitoring of in vivo metabolism of labelled tracers is based on singular value decomposition or Tucker Decomposition of magnetic resonance spectral image data. Data decomposition is used in conjunction with rank reduction to improve signal-to-noise ratio. Rank reduction can be applied in one or more of a spectral, spatial, or temporal dimension. Rank is generally reduced based on a number of expected analytes/metabolites or fit of measured data to a model.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: April 8, 2025
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Jeffrey R. Brender, James B. Mitchell, Kazutoshi Yamamoto, Shun Kishimoto, Jeeva P. Munasinghe, Hellmut Merkle, Murali K. Cherukuri
  • Publication number: 20250109175
    Abstract: Embodiments of recombinant HIV-1 gp120 proteins that contain a V1 deletion are disclosed. Also provided are gp140, gp145, and gp160 proteins containing the V1 deletion, as well as HIV-1 Env ectodomain trimers containing protomers containing the V1 deletion. Nucleic acid molecules encoding these proteins are also provided. In several embodiments, the disclosed recombinant HIV-1 proteins and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
    Type: Application
    Filed: December 5, 2024
    Publication date: April 3, 2025
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, New York University
    Inventors: Genoveffa Franchini, Timothy Cardozo, Manuel Becerra-Flores, Isabela Silva de Castro, Giacomo Gorini, Massimiliano Bissa
  • Publication number: 20250090658
    Abstract: The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.
    Type: Application
    Filed: December 5, 2024
    Publication date: March 20, 2025
    Applicants: Oxford University Innovation Limited, The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Kerry Fisher, Richard Laga, Geoffrey Lynn, Leonard Seymour, Robert Seder
  • Publication number: 20250095390
    Abstract: A method is provided for non-invasively predicting characteristics of one or more cells and cell derivatives. The method includes training a machine learning model using at least one of a plurality of training cell images representing a plurality of cells and data identifying characteristics for the plurality of cells. The method further includes receiving at least one test cell image representing at least one test cell being evaluated, the at least one test cell image being acquired noninvasively and based on absorbance as an absolute measure of light, and providing the at least one test cell image to the trained machine learning model. Using machine learning based on the trained machine learning model, characteristics of the at least one test cell are predicted. The method further includes generating, by the trained machine learning model, release criteria for clinical preparations of cells based on the predicted characteristics of the at least one test cell.
    Type: Application
    Filed: May 13, 2024
    Publication date: March 20, 2025
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Kapil Bharti, Nathan A. Hotaling, Nicholas J. Schaub, Carl G. Simon
  • Patent number: 12251432
    Abstract: Disclosed herein are immunogenic compositions for preventing or treating infection with filarial parasites and biomarkers for diagnosing infection with filarial parasites.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: March 18, 2025
    Assignees: New York Blood Center, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Sara Lustigman, Thomas B. Nutman, Sasisekhar Bennuru
  • Patent number: 12239654
    Abstract: The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 4, 2025
    Assignees: Astrocyte Pharmaceuticals, Inc., Board of Regents, The University of Texas System, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: William S. Korinek, James D. Lechleiter, Theodore E. Liston, Kenneth A. Jacobson